GMP Considerations for Co-Located API and Finished-Dose Manufacturing
GMP Considerations for Co-Located API and Finished-Dose Manufacturing Step-by-Step GMP Considerations for Co-Located API and Finished-Dose Manufacturing The pharmaceutical manufacturing landscape often necessitates the co-location of Active Pharmaceutical Ingredient (API) production with finished-dosage-form manufacturing facilities. This integrated approach offers benefits such as reduced logistics complexity, faster product turnaround, and tighter supply chain control. However, it…
Read More “GMP Considerations for Co-Located API and Finished-Dose Manufacturing” »